MEPE is a novel regulator of growth plate cartilage mineralization by Staines, Katherine et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEPE is a novel regulator of growth plate cartilage mineralization
Citation for published version:
Staines, K, Mackenzie, NCW, Clarkin, CE, Zelenchuk, L, Rowe, PS, MacRae, VE & Farquharson, C 2012,
'MEPE is a novel regulator of growth plate cartilage mineralization' Bone, vol 51, no. 3, pp. 418-430. DOI:
10.1016/j.bone.2012.06.022
Digital Object Identifier (DOI):
10.1016/j.bone.2012.06.022
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Bone
Publisher Rights Statement:
Available under Open Access
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Original Full Length Article
MEPE is a novel regulator of growth plate cartilage mineralization
K.A. Staines a,⁎, N.C.W. Mackenzie a, C.E. Clarkin b, L. Zelenchuk c, P.S. Rowe c, V.E. MacRae a, C. Farquharson a
a The Roslin Institute and Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush, Midlothian EH25 9RG, UK
b Centre for Biological Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
c Department of Internal Medicine, The Kidney Institute and Division of Nephrology, University of Kansas Medical Center, Kansas City, KS, USA
a b s t r a c ta r t i c l e i n f o
Article history:
Received 10 April 2012
Revised 21 June 2012
Accepted 23 June 2012
Available online 7 July 2012
Edited by: J. Aubin
Keywords:
MEPE
ASARM
Growth plate
Mineralization
Chondrocyte
Matrix extracellular phosphoglycoprotein (MEPE) belongs to the SIBLING protein family which play key roles
in biomineralization. Although the growth plates of MEPE-overexpressing mice display severe morphological
disruption, the expression and function of MEPE in growth plate matrix mineralization remains largely
undeﬁned. Here we show MEPE and its cleavage product, the acidic serine aspartate-rich MEPE-associated
motif (ASARM) peptide, to be localised to the hypertrophic zone of the growth plate. We also demonstrate
that the phosphorylated (p)ASARM peptide inhibits ATDC5 chondrocyte matrix mineralization. Stable
MEPE-overexpressing ATDC5 cells also had signiﬁcantly reduced matrix mineralization in comparison to
the control cells. Interestingly, we show that the addition of the non-phosphorylated (np)ASARM peptide
promoted mineralization in the ATDC5 cells. The peptides and the overexpression of MEPE did not affect
the differentiation of the ATDC5 cells. For a more physiologically relevant model, we utilized the metatarsal
organ culture model. We show the pASARM peptide to inhibit mineralization at two stages of development, as
shown by histological and μCT analysis. Like in the ATDC5 cells, the peptides did not affect the differentiation
of the metatarsals indicating that the effects seen on mineralization are direct, as is additionally conﬁrmed by
no change in alkaline phosphatase activity or mRNA expression. In themetatarsal organ cultures, the pASARM
peptide also reduced endothelial cell markers and vascular endothelial growth factormRNA expression. Taken
together these results show MEPE to be an important regulator of growth plate chondrocyte matrix mineral-
ization through its cleavage to an ASARM peptide.
© 2012 Elsevier Inc. All rights reserved.
Introduction
Linear bone growth involves the replacement of a cartilaginous
template by mineralized bone through endochondral ossiﬁcation. This
growth process is orchestrated by various actions at the growth plate,
a developmental region consisting of chondrocytes in distinct cellular
zones. The proliferation, hypertrophy and apoptosis of these growth
plate chondrocytes are regulated by a tight array of factors ensuring
effective cartilage mineralization and thus longitudinal growth [1].
Hydroxyapatite (HA) crystals form associated with the trilaminar
membrane bound matrix vesicles (MV) which in the growth plate
are localised to the mineralized longitudinal septae and form from
the plasma membrane of the terminal hypertrophic chondrocytes [2].
Mineralization is a biphasic process which is under tight control so as
to ensure levels of calcium (Ca2+) and inorganic phosphate (Pi) are per-
missive for effective HA formation [2]. Threemolecules have been iden-
tiﬁed as imperative in controlling levels of the mineralization inhibitors
inorganic pyrophosphate (PPi), and osteopontin [2,3]. These are alkaline
phosphatase (ALP), a nucleotide pyrophosphatase/phosphodiesterase
isozyme (NPP1), and the Ankylosis protein (ANK). However, mecha-
nisms beyond the supply and hydrolysis of PPi likely exist to control
chondrocyte matrix mineralization.
Once such mechanism could involve matrix extracellular phospho-
glycoprotein (MEPE, OF45). This was originally isolated and cloned
from tumors of oncogenic hypophosphatemic osteomalacia (OHO)
as a candidate substrate for phosphate-regulating gene with homol-
ogies to endopeptidases on the X chromosome (PHEX) [4]. MEPE is
a 56–58 kDa SIBLING (small integrin-binding ligand N-linked glyco-
sylated) protein alongwith dentinmatrix protein 1 (DMP1), osteopontin
(OPN), dentin sialophosphoprotein (DSPP) and bone sialoprotein (BSP)
[5]. SIBLING proteins are expressed in bone and dentin, and have roles
in extracellular matrix (ECM) formation and mineralization [6]. Their
structures are similar; all display an Arg-Gly-Asp (RGD) motif which
facilitates cell attachment, and all are commonly located on the human
chromosome 4q21-23 [4,7,8].
In bone, MEPE is primarily expressed by osteocytes, but Mepe
mRNA expression has also been observed in osteoblasts [9]. The
expression of MEPE is increased during osteoblast matrix mineraliza-
tion suggesting a function for MEPE in bone mineralization [10,11].
This has been further fuelled by analysis of the MEPE null mouse in
which the ablation of MEPE leads to an increased bone mass due to
increased numbers and activity of osteoblasts [12]. Furthermore, the
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overexpression of MEPE in mice, under the control of the Col1a1 pro-
moter, leads to defective mineralization coupled with an increased
level of MEPE-ASARM peptides in bone [13]. The MEPE-overexpressing
mice displayed wider epiphyseal growth plates, with associated ex-
panded primary spongiosa and a signiﬁcant decrease in mineral apposi-
tion rate [13]. Further studies in vitro have conﬁrmed the inhibitory
effect of MEPE on mineralization and have identiﬁed that MEPE is
cleaved to a 2.2 kDa ASARM peptide which causes this effect [14,15].
The ASARM motif is located immediately downstream of a cathepsin B
cleavage site, and it is responsible for the mineralization defect ob-
served in X-linked hypophosphatemic rickets, the most common form
of inherited rickets [4,14,15]. This defect can be reversed by adminis-
tration of cathepsin inhibitors CAO74 or pepstatin [16]. PHEX plays a
central role in the protection of MEPE from proteolytic cleavage by
cathepsin B; it can bind to MEPE and prevent the release of the ASARM
peptide [17]. The Hyp mouse, a spontaneous Phex knockout model,
has an increased expression of cathepsin D, an upstream activator of
cathepsin B [16]. Therefore PHEX may also assist in decreasing the acti-
vation of cathepsin B.
Previous studies have shown that the post translational modiﬁca-
tion of the MEPE-ASARM peptide is key to its functional role. MEPE
has a number of potential casein kinase II phosphorylation motifs,
and it is here that the ASARM peptide is phosphorylated at 3 serine
residues [4]. This has been shown to inhibit mineralization in murine
calvarial osteoblasts and in bone marrow stromal cells by the direct
binding of the MEPE-ASARM peptide to HA crystals [14,18].
To elucidate the interactions of MEPE in the growth plate, this
study was undertaken to examine the presence and function of
MEPE and its ASARM peptide in growth plate matrix mineralization
during the endochondral ossiﬁcation process. The data indicated
that MEPE is expressed by growth plate chondrocytes, in particular
in the hypertrophic zone of chondrocytes consistent with a potential
role in matrix mineralization. MEPE has a functional role in the inhi-
bition of chondrocyte ECM mineralization, involving its cleavage,
and subsequent phosphorylation, to the ASARM peptide.
Materials and methods
Animals
Proximal tibiae from 3‐ and 4‐week‐old C57/BL6 mice were dis-
sected and excess tissue was removed before preparation of the tissues
for in situ hybridization, immunohistochemistry and microdissection
of the growth plate. For metatarsal organ culture, the middle three
metatarsals were aseptically dissected from E17 and E15 C57/BL6
mice. All experimental protocols were approved by Roslin Institute's
Animal Users Committee and the animals were maintained in accor-
dancewithUKHomeOfﬁce guidelines for the care and use of laboratory
animals.
In situ hybridization
Bone tissue was ﬁxed in 10% neutral buffered formalin (Sigma,
Gillingham, UK) for 48 h at 4 °C, before being decalciﬁed in 10%
ethylenediaminetetraacetic acid (EDTA) (Sigma) pH 7.4 at 4 °C for
approximately 4 weeks with regular changes. Tissues were dehydrated
and embedded in parafﬁnwax using standard procedures, before being
sectioned at 5 μm. A full length murine MEPE cDNA IMAGE clone
(ID: 8733911) was purchased (Source BioScience UK Ltd, Nottingham).
Anti-sense and sense constructs were linearised, using Nco1, and
digoxigenin-labeled cRNA probes were synthesised using T3 and T7
RNA polymerases respectively (Roche, Burgess Hill, UK). Hybridizations
were completed following an optimised in situ hybridization protocol
as previously detailed [19].
Growth plate microdissection
Bone tissue samples were coated in 5% polyvinyl acetate and then
immersed in a cooled hexane bath for 30 s after which they were
stored at −80 °C until use. Using optimal cutting temperature
(OCT) embedding medium (Brights, Huntingdon, UK) 30 μm sections
were cut at −30 °C (Brights, OT model cryostat), and then stored at
−80 °C. Slides were brieﬂy thawed and then microdissection was
performed as previously detailed [20]. For each zone, tissue was dis-
sected from both proximal tibias of three animals (14–22 sections)
and RNA isolation was performed as previously described [21].
Immunohistochemistry
After dissection, tissue was ﬁxed in 70% ethanol for 24 h at 4 °C
before being decalciﬁed in 10% EDTA (pH 7.4) for approximately
4 weeks at 4 °C with regular changes. Tissues were ﬁnally dehydrated
and embedded in parafﬁn wax, using standard procedures, after
which they were sectioned at 5 μm. For immunohistochemical analy-
sis, sections were dewaxed in xylene and rehydrated. Sections were
incubated at 37 °C for 30 min in 0.1% trypsin (Sigma) for antigen
demasking. Endogenous peroxidases were blocked by treatment
with 0.03% H2O2 in methanol (Sigma). From this point onwards, the
Vectastain ABC (Goat) kit (Vector Laboratories, Peterborough) was
used according to the manufacturer's instructions. ASARM and MEPE
primary antibodies were used at a dilution of 1/200 with rabbit IgG
used as a control [13]. Cathepsin B primary antibodies (R&D Systems,
Abingdon, UK)were used at a dilution of 2 μg/mlwith goat IgG used as
an appropriate control. The sections were dehydrated, counterstained
with haematoxylin and mounted in DePeX.
MEPE‐ASARM peptides
MEPE-ASARM peptides were synthesised (Peptide Synthetics, UK)
as phosphorylated ASARM (pASARM) with the sequence RDDSSESSD
SG(Sp)S(Sp)SSE(Sp)SDGD, andnon-phosphorylatedASARM(npASARM)
with the sequence RDDSSESSDSGSSSESDGD. pASARM and npASARM
peptides were added to ATDC5 cells and metatarsal organ cultures at
concentrations of 10, 20 and 50 μM, with controls treated with a DMSO
(Sigma) carrier only. In further studies, peptides were added at a ﬁnal
concentration of 20 μM with experiments being performed at least 3
times.
Metatarsal organ culture
Embryonic metatarsal organ cultures provide a well‐established
model of endochondral bone growth [22–24]. Metatarsal bones were
cultured in a humidiﬁed atmosphere (37 °C, 5% CO2) in 24-well plates
for up to 10 days. Each culture well contained 300 μl α-minimum
essential medium (MEM) supplemented with 0.2% BSA Fraction V;
1 mmol/lβ-glycerophosphate (βGP); 0.05 mg/ml L-ascorbic acid phos-
phate; 0.05 mg/ml gentamicin and 1.25 μg/ml fungizone (Invitrogen,
Paisley, UK) as previously described [22]. For the E17 bones, the medi-
um was changed every second or third day and for the E15 bones, the
medium was not changed throughout the culture period [25]. Concen-
trations of peptide andDMSO carrierwere however added every second
day.
Morphometric analysis of metatarsals
The total length of the bone through the centre of the mineralizing
zone was determined using image analysis software (DS Camera
Control Unit DS-L1; Nikon) every second or third day. The length of
the central mineralization zone was also measured. All results are
expressed as a percentage change from harvesting length which was
regarded as baseline.
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3D-Microtomography of metatarsals
Metatarsals were ﬁxed in 70% ethanol, stained with eosin dye
(for visualisation) and then embedded in parafﬁn blocks. Samples
were then were scanned with a high-resolution μCT (μCT40; Scanco
Medical, Southeastern, PA) as previously described [13,16]. Data
were acquired at 55 KeV with 6 μm cubic voxels. Three-dimensional
reconstructions for bone samples were generated with the following
parameters: Gauss Sigma=4.0; Support=2, Lower Threshold=90
and Upper Threshold =1000. Tissue mineral density was derived
from the linear attenuation coefﬁcient of threshold bone through
precalibration of the apparatus for the acquisition voltage chosen.
The bone volume (BV/TV)wasmeasured using sections encompassing
the entire metatarsal on a set of 85 sections that was geometrically
aligned for each sample.
Metatarsal [3H]-thymidine proliferation assay
Onday 7 of culture, 3 μCi/ml [3H]-thymidine (AmershamBiosciences,
Little Chalfont, UK) was added to each metatarsal for the last 6 h of
culture [22]. After washing in PBS, the unbound thymidine was
extracted using 5% trichloroacetic acid (Sigma). Metatarsals were then
washed in PBS before being solubilised (NCS-II tissue solubiliser,
0.5 N, Amersham) at 60 °C for 1 h. [3H]-thymidine incorporated into
DNA was determined using a scintillation counter.
Cell culture
Chondrogenic ATDC5 cells (RIKEN cell bank, Ibaraki, Japan) were
utilized as a well-established model of chondrocyte matrix minerali-
zation with previous studies detailing their chondrogenic differen-
tiation and subsequent mineralization [26]. Cells were cultured in
differentiation medium (DMEM/F-12 (1:1) with GlutaMAX I con-
taining 5% FBS, 1% insulin transferrin and selenium, 1% sodium pyru-
vate and 0.5% gentamicin (Invitrogen)) at a density of 6000 cells/cm2.
10 mM beta-glycerophosphate (βGP) and 50 μg/ml ascorbic acid
were added once the cells had reached conﬂuency. Cells were incu-
bated in a humidiﬁed atmosphere (37 °C, 5% CO2) for up to 15 days
with medium changed every second or third day.
Plasmid construction
The full length murine MEPE cDNA (IMAGE clone ID: 8733911)
was supplied within a pCR4.TOPO vector (Source BioScience UK Ltd,
Nottingham). The cDNA sequence was excised by digestion with
EcoRI and sub-cloned into the pEN.Tmcs (MBA-251; LGC Standards,
Middlesex, UK) using T4 DNA ligase (Roche). The expression vector
pLZ2-Ub-GFP (kind gift from D. Zhao, Roslin Institute) was digested
with BamHI and XbaI to remove the GFP cDNA. The MEPE cDNA was
excised from the pEN.T-MEPE sub-cloning vector using BamHI and
XbaI and ligated into pLZ2-Ub backbone to create a Ubiquitin driven
MEPE expression construct, pLZ2-Ub.MEPE. To create the empty vec-
tor control (pLZ2-Ub.EMPTY) the pLZ2-Ub backbone was blunted
using T4 polymerase (New England Bioscience, Hitchin, UK) and
re-ligated.
Establishment of stable MEPE-overexpressing ATDC5 cells
ATDC5 cells were maintained in differentiation medium as previ-
ously described and seeded at 150,000 cells/cm2. Cells were trans-
fected with pLZ2-Ub.MEPE and pLZ2-Ub.EMPTY constructs at a ratio
of 7:2 FuGENE HD (Roche) to DNA, according to the manufacturer's
instructions. Blasticidin resistant colonies were picked using cloning
cylinders (Sigma), expanded, frozen and maintained at −150 °C until
further use. Three MEPE-overexpressing and three empty vector clones
were picked for analysis.
Real-time quantitative PCR (RT-qPCR)
RNA was extracted from ATDC5 cell cultures using an RNeasy mini
kit (Invitrogen) according to the manufacturer's instructions. For
metatarsal organ cultures, 4 bones from each control or experimental
group were pooled in 100 μl Trizol reagent (Invitrogen) at days 5 and
7 of culture, and RNA was extracted according to the manufacturer's
instructions. For each sample, total RNA content was assessed by
absorbance at 260 nm and purity by A260/A280 ratios, and then
reverse-transcribed. RT-qPCR was performed using the SYBR green
detection method on a Stratagene Mx3000P real-time qPCR system
(Stratagene, CA, USA), or a LC480 instrument (Roche). Primers were
purchased (PrimerDesign Ltd, Southampton, UK) or designed in house
and synthesised by MWG Euroﬁns, London, UK, or Sigma. Sequences
are detailed in Supplemental Table S1. Reactions were run in triplicate
and routinely normalized against 18S or β-actin.
Endpoint PCR analysis
Expression of speciﬁc pro-angiogenic vascular endothelial growth
factor (VEGF)-A isoforms namely VEGF120,164 and 188 was analysed as
previously detailed [27]. The VEGF isoform primer sequences were:
forward GAAGTCCCATGAAGTGATCCAG and reverse TCACCGCCTTGG
CTTGTCA. Located on exon 3 (forward) and exon 8 (reverse), these
amplify all the isoforms of murine VEGF. Different isoform mRNA
expression proﬁles were identiﬁed in a 2.5% agarose (Sigma) gel
according to the molecular weight of PCR products using cDNA
synthesised from equal amounts of RNA. Product band densities were
analysed using Image J software (U. S. National Institutes of Health,
Maryland, USA).
Histological procedures
After 15 days of culture, calcium and collagen deposition in ATDC5
cells were evaluated by alizarin red stain (Sigma) and sirius red stain
(Biocolor Ltd., Newtownabbey, UK) respectively [28]. Cells were ﬁxed
in 4% paraformaldehyde following washes with PBS. 2% alizarin red
(pH 4.2) was added to the cell layers for 5 min at room temperature
and then rinsed off with distilled water. Alizarin red-stained cultures
were extracted with 10% cetylpyridinium chloride for 10 min [28–30].
Sirius red was added to cell cultures for 1 h at room temperature before
being rinsed with distilled water. 0.001 M hydrochloric acid was then
used to remove unbound dye. To quantify staining, 0.1 M sodium
hydroxide was used for 30 min. The optical density (OD) of the alizarin
red and sirius red digests was measured at 570 nm by spectrophotom-
etry (Multiskan Ascent, Thermo Electron Corporation, Vantaa, Finland).
Proteoglycan synthesis contentwas evaluated by staining the cell layers
with alcian blue (Sigma). Cells were ﬁxed in 95% methanol for 20 min
and stained with 1% alcian blue 8GX in 0.1 M HCl overnight. Alcian
blue-stained cultures were extracted with 1 ml of 6 M guanidine–HCl
for 6 h at room temperature and the OD was determined at 630 nm
by spectrophotometry [28].
Alkaline phosphatase enzyme activity
At the end of the culture period, alkaline phosphatase (ALP) activ-
ity within the metatarsal bones was determined using an assay for
ALP (Thermo Fisher Scientiﬁc, Epsom, UK) according to the man-
ufacturer's instructions. Brieﬂy, each metatarsal was permeabilized
in 100 μl of 10 mmol/l glycine (pH 10.5) containing 0.1 mmol/l
MgCl2, 0.01 mmol/l ZnCl2, and 0.1% Triton X-100 by freeze-thawing
three times [22]. Each extract was assayed for ALP activity by measur-
ing the rate of cleavage of 10 mM p-nitrophenyl phosphate. Total
ALP activity was expressed as nanomoles p-nitrophenyl phosphate
hydrolysed per minute per bone.
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Lactate dehydrogenase activity
Lactate dehydrogenase (LDH) activity was determined in the cul-
ture medium of 15-day-old 0 mM and 10 mM βGP treated ATDC5
cells using a kit from Roche Diagnostics (Lewes, East Sussex, UK).
LDH activity was related to the total LDH activity of the cultures.
Statistical analysis
Data were analysed by one-way analysis of variance (ANOVA), the
Student's t-test, or a suitable non-parametric test using Sigma Plot 11
(Germany). All data are expressed as the mean±SEM.
Results
The expression of MEPE in the murine growth plate
To assess the expression of MEPE by growth plate chondrocytes
we examined Mepe mRNA localization in the murine growth plate of
3-week-old mice by in situ hybridization. Mepe was expressed abun-
dantly by growth plate chondrocytes and by osteoblasts within the
metaphysis (Fig. 1A). In the growth plate, high levels of Mepe mRNA
were observed, especially in the hypertrophic chondrocytes (Fig. 1B
and C). This spatial expression pattern was further examined and
quantiﬁed by microdissection of growth plates. To validate the micro-
dissection technique, RT-qPCR of collagen type X mRNA expression
was conducted to ensure that the hypertrophic zone could be consid-
ered as an enriched pool of hypertrophic chondrocytes (Fig. 1D). There
was approximately a 10-fold increase in collagen type X mRNA ex-
pression in the hypertrophic zone in comparison to the proliferative
zone (Pb0.001). This is in concordance with previous studies done
using a similar technique [31]. Mepe mRNA had a signiﬁcantly higher
expression (Pb0.05) in the hypertrophic zone in comparison to the
proliferative zone of the growth plate (Fig. 1E). Immunolocalization
of MEPE and the MEPE-ASARM peptide in 4-week-old growth plates
veriﬁed the in situ hybridization and microdissection data as demon-
strated by its localization to the hypertrophic zone of chondrocytes
(Fig. 1F and H). This ASARM peptide is cleaved from MEPE by cathep-
sin B; thus, we examined the immunolocalization of cathepsin B in
the growth plate (Fig. 1J). Here we show it to be expressed at the
chondro-osseous junction as is in concordance with previous studies
[32,33]. Representative images of the appropriate negative controls
are shown (Fig. 1G, I and K). Together these data indicate that
MEPE-ASARM peptide is preferentially expressed by hypertrophic
chondrocytes of the growth plate and this localization is consistent
with a role for this peptide in regulating cartilage mineralization.
The functional role of MEPE in ATDC5 cells
It is known that the C-terminal fragment is the active form of
MEPE. This fragment contains the ASARM peptide; thus, we next
determined the role of the ASARM peptide in chondrocyte matrix
mineralization by examining the mineralization capability of ATDC5
cells in response to MEPE-ASARM peptides. The ATDC5 cell line is a
teratocarcinoma derived cell line which has been shown to display
the multistep chondrogenic differentiation process, from mesenchy-
mal condensation to matrix mineralization [26,34], at approximately
day 15 of culture. The culture method used here did not result in
metabolic stress leading to cell death as indicated by assessment of
released LDH activity as a percentage of total LDH release (0 mM
βGP 33.5%±2.5, 10 mM βGP 35.2%±0.9, NS). Here we added pAS-
ARM and npASARM peptides to ATDC5 cell cultures under calcifying
conditions over a 15-day culture period. There was no apparent
morphological difference between control and ASARM-treated cells.
pASARM peptides inhibited mineralization in a dose-dependent man-
ner as visualised by alizarin red staining and quantiﬁed by
spectrophotometry (at 20 μM and 50 μM in comparison to control;
Pb0.01) (Fig. 2A). Interestingly, it was found that npASARM promot-
ed mineralization over the 15-day culture period (at 20 μM and
50 μM in comparison to control; Pb0.01) (Fig. 2B). Given that MEPE
has been postulated to have direct effects on osteoblast mineraliza-
tion and not via altered matrix production [14,18], we investigated
whether this was the case with ATDC5 cells by examining their ability
to produce their collagenous matrix when treated with the
MEPE-ASARM peptides. Collagen deposition (Fig. 2C) and glycosami-
noglycan production (Fig. 2D), as visualised by sirius red and alcian
blue stains, respectively, were unaffected by addition of 20 μM pAS-
ARM or npASARM peptide. These data are therefore supportive of a
direct role for MEPE-ASARM peptides in chondrocyte matrix
mineralization.
We next overexpressed MEPE in ATDC5 cells to examine this
functional role further. When cultured under calcifying conditions,
MEPE-overexpressing cells showed an inhibition of matrix minerali-
zation throughout the culture period as visualised by alizarin red
staining and quantiﬁed by spectrophotometry (at day 8 in compari-
son to empty vector control Pb0.01, at days 12 and 15 in comparison
to empty vector control Pb0.001) (Fig. 3A). RT-qPCR ampliﬁcations
showed that stable individualMEPE-overexpressing ATDC5 cell clones
expressed signiﬁcantly higher Mepe mRNA levels than individual
empty vector clones (Pb0.001) (Fig. 3B). Phex mRNA levels were
signiﬁcantly decreased in theMEPE-overexpressing clones in compar-
ison to the empty vector controls (Pb0.05) (Fig. 3C). Chondrocyte
marker genes of differentiation and mineralization were examined
for mRNA expression and no differences were found between the
MEPE-overexpressing and the empty vector controls (Fig. 3D and E,
Supplemental Fig. S1).
Phosphorylated MEPE-ASARM peptides inhibit the mineralization
capability of E17 metatarsal bones
We next wanted to examine the effects of the MEPE-ASARM pep-
tides on a more physiologically relevant model. Primary chondrocytes
provide difﬁculties when culturing as they tend to dedifferentiate
to a ﬁbroblastic-like phenotype during long-term culture [35–38];
thus, we utilized the metatarsal organ culture model. When dissected,
E17 mice metatarsals display a central core of mineralized cartilage
juxtaposed by a translucent area on both sides representing the hy-
pertrophic chondrocytes [22] (Fig. 4B). These bones were cultured
in the presence of varying concentrations of pASARM and npASARM
peptides over a 10-day period to examine their effects on longitudinal
bone growth and the growth of the central mineralization zone.
This preliminary data indicated that MEPE-ASARM peptides inhibit
mineralization of metatarsal bones across a range of concentrations
(Supplemental Fig. S2). Due to the physiological relevance of 20 μM
in XLH patients andHypmice, this concentrationwas used throughout
these experiments [18]. Bones treated with 20 μMMEPE-ASARM pep-
tides grew in length at the same rate as the control bones (up to 80%)
after 7 days in culture (Fig. 4C–F). However, whereas in the control
and npASARM treated metatarsals the central mineralization zone
increased in length throughout the culture period (increased approx-
imately 5–6 fold from initial lengths, Fig. 4D and E), in the pASARM
treated cultures no changes in length were noted (Pb0.01 at day 6,
Pb0.001 at days 8 and 10 in comparison to the control) (Fig. 4C, E
and G).
The effects of the MEPE-ASARM peptides on E15 metatarsal bones
To examine this apparent inhibitory effect further, we next deter-
mined the effects of the pASARM and npASARM peptides on E15 meta-
tarsal bones. These bones consist of early proliferating chondrocytes
(Fig. 5A) and no evidence of a mineralized core. After 7 days in culture,
the chondrocytes in the centre of the bone become hypertrophic and
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mineralize their surrounding matrix as is previously documented [25]
(Fig. 5B). This central core of mineralized cartilage formed in control
bones and bones treated with 20 μM npASARM peptides (Fig. 5B and
C); however, it was minimal in metatarsal bones treated with 20 μM
pASARM peptides (Fig. 5D), as seen in the phase contrast images. This
was further conﬁrmed by von kossa staining of histological sections
for mineralization (Fig. 5H) and by μCT scanning of the metatarsal
bones to allow the visualisation of the bones in a 3D context. In compar-
ison to the control and npASARM treated bones, metatarsal bones cul-
tured in the presence of pASARM peptides had a signiﬁcantly reduced
BV/TV (Pb0.001) (Fig. 5I), as is clearly visible in the μCT scan images
(Fig. 5J). This unequivocally shows the inhibition of mineralization in
metatarsal bones by the pASARM peptide. Despite the increase in
ATDC5 ECM mineralization upon addition of npASARM peptides, here
themeandensity of themineralised bonewas unchanged between con-
trol and npASARM treated bones (control 163.4±12.1 mg HA/ccm,
npASARM 173.2±21.9 mg HA/ccm, not signiﬁcant).
Apart from the inhibition of mineralization by the pASARM pep-
tide, there were no other obvious morphological differences in the
development of these bones in comparison to the control bones.
Fig. 2. Mineralization of ATDC5 matrix in the presence of (A) pASARM and (B) npASARM peptides was visualised by alizarin red staining (images) and quantiﬁed after 15 days of
culture. Quantiﬁcation of sirius red staining (C) and alcian blue staining (D) (images) of ATDC5 cells following 15 days of culture with 20 μM pASARM and npASARM peptides. Data
are represented as mean±SEM of three wells analysed in triplicate. **Pb0.01.
Fig. 1. In situ hybridization ofMepe in 3-week-oldmouse tibia.Mepewas found to be abundantly expressed by growth plate chondrocytes and osteoblasts of themetaphysis (A). Expres-
sion was present in both the proliferating zone (PZ) and the hypertrophic zone (HZ) of the growth plate, as indicated by the arrows (B), with an apparent increase in expression in the
hypertrophic zone of chondrocytes (C).Microdissection of the growth platewas adopted to assessMepemRNAexpression. The accuracy of themicrodissection techniquewas determined
by the relative change in col10a1mRNA expression throughout the zones of the growth plate and the trabecular bone (D). This was then used to examine the relative change inMepe
mRNA expression in these zones (E). Immunohistochemistry shows MEPE (F and G) and the MEPE-ASARM peptide (I and J) to be expressed in the tibia of 4-week-old growth plates.
Its expression in the growth plate is limited to the hypertrophic zone (HZ) of chondrocytes, as indicated by the arrows. Cathepsin B immunolocalization (L and M) was exclusive to
the chondro-osseous junction, as highlighted by the arrows. Representative images of appropriate negative control are shown (H, K, andN). Values generated by RT-qPCR and normalized
to 18S. Data are represented as mean±SEM, in comparison to the PZ, *Pb0.05 **Pb0.005. Scale bars are (A, B, F, H, I, K, L, N) 0.5 mm, (C) 0.1 mm, and (G, J, M) 0.01 mm.
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All bones grew at the same rate (increased approximately 65% from
initial lengths) (Fig. 5E) and by incorporating [3H]-thymidine into
the bones at the end of the culture period, day 7, it was determined
that the proliferation rate of the chondrocytes was unchanged
(Fig. 5F). The lengths of the proliferating (PZ) and hypertrophic
(HZ) zones of chondrocytes were also measured. The MEPE-ASARM
peptides had no effect on the percentage sizes of the maturational
zones of the metatarsal bones, or on the cell numbers within the
bones (Control: 1139.13±172.01, pASARM: 1594.97±226.9, npASARM
1233.71±126.08). This therefore suggests that the MEPE-ASARM
peptides had no effect on the differentiation capability of the metatarsal
chondrocytes (Fig. 5G). To examine this further, we looked at mRNA
expressions of chondrocyte differentiation markers for which there
were no signiﬁcant differences between the control and pASARM treated
bones at days 5 and 7 of culture (Supplemental Fig. S3, Supplemental
Fig. S4) as is in concordance with our histological and proliferation data.
We also examined the expression and activity of key enzymes as-
sociated with cartilage mineralization to establish whether these are
involved in the mechanism of inhibition by the pASARM peptides. In-
terestingly there was no signiﬁcant difference in the activity of ALP
(Fig. 6A), a well recognised regulator of chondrocyte matrix mineral-
ization. This was further conﬁrmed by mRNA expression analysis of
Alpl by RT-qPCR (Fig. 6B). Analysis of the mRNA expression of other
mineralization regulators, Ank, Enpp and Phospho1, also showed no
difference between control and treated bones at days 5 and 7 of cul-
ture (Supplemental Figs. S3 and S4).
To assess the possible interactions of PHEX with MEPE, we exam-
ined mRNA expression of Phex and found it to be signiﬁcantly de-
creased in the pASARM treated bones compared to the control bones
at day 7 of culture (Pb0.05) (Fig. 6C). Furthermore, Mepe mRNA
expression was signiﬁcantly increased (Pb0.001) (Fig. 6D). At day 5
of culture, there was no signiﬁcant difference in the mRNA expression
of Mepe or Phex (Supplemental Fig. S3).
The vascular invasion of the cartilage model via VEGF stimulated
angiogenesis is critical for matrix mineralization [39]. Thus, we exam-
ined the effects of the pASARM peptide on the mRNA expression of
endothelial cell speciﬁc markers and VEGF. We found a signiﬁcant
decrease in the expression levels of Cd31, Cd34, and VEGFR2/Flk1 fol-
lowing 7 days of culture in the presence of 20 μM pASARM compared
to controls (Pb0.01, Pb0.05) (Fig. 7A–C). Furthermore, we also found
a concomitant decrease in VEGF isoform expression speciﬁcally
VEGF164 and 120 (Fig. 7D–F). VEGF188 was not detected in either con-
trol or treated metatarsals. Matrix metalloproteinase 13 (MMP13),
which has been implicated in VEGF-induced angiogenesis [40,41],
also had a signiﬁcantly decreased mRNA expression following 5 days
of culture (in pASARM treated bones compared to control; Pb0.05)
(Fig. 7G). Despite this there was histologically no apparent inhibition
of vascularization in the metatarsal bones.
Discussion
The hypertrophic chondrocytes of the epiphyseal growth plate
mineralize their surrounding ECM and facilitate the deposition of HA,
a process imperative for longitudinal bone growth. It is widely accepted
that ALP, NPP1 and ANK are all central regulators of levels of PPi, a min-
eralization inhibitor, and thus the deposition of HA [42–46]. Recently
it has come to light that mechanisms beyond the supply and hydrolysis
of PPi also exist to control matrix mineralization. Studies into rare
genetic disorders, such as X-linked hypophosphatemic rickets (XLH),
have identiﬁed a family of proteins, FGF23, PHEX, and MEPE which act
through a bone-kidney axis to modulate phosphate homeostasis and
thus bone mineralization indirectly [4,47–49]. However, these proteins
have been shown to have direct effects on mineralization, independent
of the bone-kidney axis [50,51]. Herewe provide evidence forMEPE as a
novel regulator of growth plate cartilage mineralization.
Fig. 3.MEPE-overexpressing ATDC5 cells showed inhibited mineralization in comparison to empty vector cells at days 8, 12 and 15 of culture as visualised by alizarin red staining
and quantiﬁed by spectrophotometry (A). Mepe mRNA expression was signiﬁcantly increased in MEPE-overexpressing ATDC5 clones (B), whilst Phex mRNA expression was sig-
niﬁcantly decreased in comparison to empty vector controls (C). There was no difference in mRNA expression levels of (D) Col2a1 or (E) Alpl. Data are represented as mean of
3 clones±SEM. *Pb0.05, **Pb0.01, ***Pb0.001.
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MEPE is a member of the SIBLING family of proteins and is
expressed by mature osteoblasts, osteocytes, odontoblasts and the
proximal convoluted tubules of the kidney [12,16,52,53]. It is degrad-
ed by cathepsin B to an acidic, negatively charged ASARM peptide
which inhibits osteoblast matrix mineralization by directly binding
to HA [14,15,18]. Patients with XLH have elevated serum levels of
this ASARM peptide as does the mouse model of XLH, the Hyp mouse
[54]. Further studies of the Hyp mouse show severe morphological
disruption of the growth plate which can be corrected by the adminis-
tration of cathepsin inhibitors [16]. This growth plate disruption is
also observed in mice overexpressing MEPE [13]. Here we provide
evidence of the spatial localization pattern of MEPE and its mRNA in
the growth plate; more speciﬁcally we have shown it to be predomi-
nantly expressed by the terminally differentiated hypertrophic cho-
ndrocytes. It is recognised that due to the binding nature of MEPE to
HA, EDTA decalciﬁcation may in fact provide an underestimation of
the total MEPE/ASARM protein produced however the results seen
here are consistent with those observed in the MEPE-overexpressing
mouse and with a presumed role for MEPE in regulating the ﬁne bal-
ance of mineral formation at the growth plate. The localization of
cathepsin B at the chondro-osseous junction is in concordance with
previous studies detailing the cathepsin B rich septoclast [32,33].
These cells, thought to be of macrophage or osteoclast origin, are pos-
tulated to play a key role in the degradation of unmineralized cartilage
[33]. It is likely that the cathepsin B provided at the chondro-osseous
junction cleavesMEPE at its distal COOH-region to the ASARMpeptide
whichwe have shown here to be localised exclusively to the hypertro-
phic chondrocyte region.
Previous studies have shown the ASARM peptide to inhibit matrix
mineralization in in vitro osteoblast cultures [15,18,55]. It is well
recognised that the post translational phosphorylation of the MEPE-
ASARM peptide is essential for its inhibitory role. Here we utilized
the metatarsal organ culture model, a well‐established model of car-
tilage mineralization and endochondral bone growth. Developmen-
tally in mice by E15, the point at which we use metatarsal bones in
these studies, despite a considerable degree of periosteal ossiﬁcation
occurring in the long bones, the metatarsal bones exist as a cartilage
model. Here our results unequivocally show that the phosphorylated
ASARM peptide (pASARM) has a signiﬁcant inhibitory role on chon-
drocyte matrix mineralization. Here we report no difference in the
widths of the cartilage zones in the metatarsal bones. A widening of
the hypertrophic zone would be expected as seen in
Fig. 4. Measurements of digital images of E17 mouse metatarsal bones in culture with clearly delineated mineralizing zones (B–D) were taken using a calibrated ruler (A). Images
clearly show the harvesting length (B) with the locations of the proliferating (PZ), hypertrophic (HZ) andmineralizing (MZ) zones, as well as the total lengthmeasurement. A control
metatarsal bone is illustrated in (C) and bones treated with continuous 20 μM npASARM (D) and pASARM peptides (E) after 10 days of culture. The growth rate of the embryonic
metatarsal bones was not affected by treatment with 20 μMMEPE-ASARM peptides (F) when cultured for up to 10 days. There was no signiﬁcant difference in the percentage change
in mineralization length between control and npASARM treated bones, both of which increased over the culture period. However the mineralization zone length in bones treated
with pASARM peptides remained the same during the culture period (G). Data are represented as mean±SEM of six bones. **Pb0.01, ***Pb0.001 in comparison to control bones
at equivalent days of culture. Error bars are too small to be visualised.
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hypophosphatemic rickets, and as is observed in the
MEPE-overexpressing mouse [13]. This is not surprising though as
there was also no difference in the growth potential, chondrocyte
proliferation or mRNA expression of chondrocyte differentiation
markers, of the treated and untreated bones. This therefore suggests
that the MEPE-ASARM peptide has no effect on chondrocyte function
per se. Instead it affects chondrocyte matrix mineralization directly,
as is in concordance with studies done on bone mineralization
[14,18].
It is well recognised that ALP activity is a key regulator of cartilage
matrix mineralization. ALP is located to the outer surface of the
trilaminar membrane of MVs, which form from the hypertrophic
chondrocytes [56]. It is widely accepted that ALP generates Pi for HA
formation and its lack of activity results in an excess of PPi [57]. The
interaction between ALP, PPi and other SIBLING proteins has previ-
ously been documented [57,58]. It was therefore postulated that
the effects of the pASARM peptide could act through a decrease in
ALP activity/expression as has been shown in a previous study of
bone mineralization and as is observed in the MEPE‐overexpressing
mouse [13,14]. However here we show no effect on ALP activity or
expression by the ASARM peptide and as is in concordance with a
previous study investigating the role of MEPE in osteoblast miner-
alization [18]. No effect was also seen on PHOSPHO1 expression,
which together with ALP regulates bone and cartilage mineralization
suggesting that in the models utilized here, the mechanism of inhibi-
tion is not a result of decreased enzyme activity [59,60]. Rather, it is
likely that the pASARM peptide exerts its effects through its direct
binding to the HA as has previously been suggested.
It has recently been shown that a truncated form of MEPE,
which has the ASARM peptide removed, can promote bone miner-
alization in culture and in mice [61]. Furthermore, a mid-terminal
fragment of MEPE has been shown to enhance cell binding and
taken together these results highlight the importance of the post
translational processing of MEPE in determining its functional
role [62]. Here we have shown that the phosphorylation of the
ASARM peptide is crucial in determining its functional role. Despite
Fig. 6. Alkaline phosphatase (ALP) activity was unchanged in metatarsal bones treated with 20 μM pASARM peptides in comparison to control bones (A). AlplmRNA expression was
also unchanged (B). Phex mRNA expression was signiﬁcantly decreased in pASARM treated bones (C) whilst Mepe mRNA expression was increased (D). Data are represented as
mean±SEM. *Pb0.05 ***Pb0.001 of 3 groups of 4 pooled bones at day 7 of culture.
Fig. 5.Measurements of digital images of E15 mouse metatarsal bones in culture. At time of harvesting, bones did not have a central mineralization zone as indicated by the asterisk
(A). After 7 days in culture, control (B) and npASARM (C) treated bones formed a large mineralization zone; however, this was inhibited in pASARM treated bones (D). All meta-
tarsal bones grew at a similar rate (E) and there was no difference in the proliferation of the chondrocytes within (F). Histological sections (H) showed control and npASARM treat-
ed bones to have abundant mineral as indicated by von kossa staining. This was not seen in pASARM treated metatarsals. There was no difference in the widths of the proliferating
zone (PZ) and hypertrophic zone (HZ) of chondrocytes between the different groups of metatarsals at either day 5 or day 7 of culture (G). Data are represented as mean±SEM of six
bones. μCT analysis of metatarsal bones treated with npASARM and pASARM peptides. Bones treated with pASARM had a signiﬁcantly reduced BV/TV in comparison to the control
and npASARM treated bones (I). This was clearly visible in the μCT images (J). Data are represented as mean±SEM of three bones. ***Pb0.001.
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Fig. 7. mRNA expression of endothelial cell markers Cd31 (A), Cd34 (B), and VEGFR2/Flk1 (C) in control and pASARM treated bones at day 7 of culture. PCR analysis of pro-angiogenic VEGF-A splice variants (D) and densitometry of the
VEGF164 isoform (E) and the VEGF120 isoform (F). mRNA expression ofMmp13 in control and pASARM treated bones at day 5 of culture (G). Data are represented as mean±SEM. *Pb0.05, **Pb0.01 of 3 groups of 4 pooled bones. PCR analysis
represents replicates of pooled bones at day 7 of culture.
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the observed promotion of mineralization by the npASARM peptide
in the ATDC5 cultures, this was not corroborated by our metatarsal
data. Furthermore in other in vitro studies, it has been shown that
the function of the MEPE-ASARM peptide is entirely dependent
upon its phosphorylation [14,18,63]. Indeed it is likely that the
npASARM peptide does not physiologically exist and is in fact inac-
tive. One can reasonably infer that since the pASARM serine-
phosphorylated casein kinase sites are highly conserved across
species (including whales, dolphins, primates, rodents, marsupials,
elephants, dogs, and cats) and the phosphorylated form is active
that there might be a physiological mechanism that plays a role in
regulating the ASARM-phosphorylation status [64].
PHEX protects MEPE from cathepsin B cleavage in vitro [17,65];
thus, the inhibition of Phex mRNA expression in pASARM treated
metatarsal bones and in ATDC5 cells overexpressing MEPE suggests
a feedback mechanism by which ASARM peptides can prevent PHEX
expression. This, in correlation with an increase in Mepe expression
seen, would allow the release of ASARM peptides therefore further
increasing the inhibition of mineralization. Furthermore, the reduc-
tion in Phex mRNA expression may be due to the ASARM peptide
protecting itself from sequestration and hydrolysis by PHEX, as has
previously been suggested [14,18,66]. A decrease in Phex mRNA has
also been observed in osteoblast cell cultures treated with the pAS-
ARM peptide, concomitant with an increase in FGF23 expression [14].
In the MEPE-overexpressing mouse, however, an increase in Phex
mRNA is observed and this, coupled with the expected hydrolysis of
the ASARM peptide, leads to altered MEPE processing and therefore
the hyperphosphatemia observed in this mouse model [13]. These
data are also in agreement with previous reports showing increased
MEPE expression by osteoblasts of HYP mice and this positive regula-
tion of MEPE expression by pASARM may exacerbate the condi-
tion [4,10,15,66]. It is reasonable to speculate that physiologically
there must be a regulatory mechanism to ensure that there is not
an overproduction of ASARM peptides and as such a pathological
state. The precise nature of the counter balancing mechanism is pres-
ently unknown but as the SIBLING proteins are closely related and it
is possible that one of the other members of this family may be
responsible.
Key to endochondral ossiﬁcation is the vascularization of the
mineralized matrix [39]. Matrix metalloproteinases (MMPs) proteo-
lytically degrade the mineralized cartilage matrix, facilitating blood
vessel penetration into the growth plate and allowing the recruitment
of osteoclast precursors and osteoblast progenitors. Pro-angiogenic
VEGF is produced by hypertrophic chondrocytes of the growth plate
and VEGF164/188 deletion from the cartilage of developing mice results
in delayed recruitment of blood vessels to the perichondrium along
with a delayed invasion of vessels into the primary ossiﬁcation centre
[67]. Here we have shown that the pASARMpeptide reduces the levels
of endothelial cells present during metatarsal organ culture due to
the vessel invasion of the bones at approximately E14– E15. This was
associated with reduced VEGF120/164 mRNA expression levels. It is
entirely possible that the inﬂuence of the pASARM peptide on endo-
thelial cell populations is indirect, by impacting hypertrophic chon-
drocyte VEGF expression. However, any direct effects of the pASARM
peptide on endothelial cell function remain uninvestigated. The possi-
ble implications of MEPE on bone renal vascularization have recently
been described in the MEPE-overexpressing mouse, which in contrast
to our studies exhibits defective mineralization associated with
increased blood vessels [13]. Similarly, we also found a decrease in
Mmp13 mRNA expression following pASARM treatment which has
been implicated in angiogenesis despite there being a lack of impair-
ment of vascularization in the Mmp13 knockout mouse [40,41,68]. It
is likely that in the Mmp13 knockout and the Mepe-overexpressing
mice, unknown compensatory mechanisms could exist to allow for
effective vascularization of the skeleton. Like MEPE, DMP1, another
SIBLING protein, has also been suggested as an inhibitor of VEGF
receptor 2 mediated angiogenesis although the precise role of its
ASARM peptide in this circumstance has yet to be elucidated [69].
To conclude, our studies detail for the ﬁrst time the functional role
that MEPE and its ASARM peptide have in chondrocyte matrix miner-
alization. We have shown MEPE to be expressed by growth plate
chondrocytes, in particular in the hypertrophic zone of chondrocytes
consistent with a role in matrix mineralization. We have shown this
role to be dependent upon the extent of the cleavage and subsequent
phosphorylation of MEPE, and that mechanisms may exist which pos-
itively regulate the further expression of MEPE. Our studies comple-
ment previous ﬁndings of MEPE and its role in biomineralization;
however, much remains to be learnt regarding the in vivo role of
MEPE and the ASARM peptide in bone disease.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.bone.2012.06.022.
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